¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"trypsinogen activation peptide"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® peptide ÇÑ±Û ÆéƼµå
¼³¸í   
  µÎ °³ÀÌ»óÀÇ ¾Æ¹Ì³ë»ê ºÐÀÚ »çÀÌ¿¡¼­, ÇÑÂÊÀÇ ¾Æ¹Ì³ë±â¿Í ´Ù¸¥ ÂÊÀÇ Ä«¸£º¹½Ç±â°¡ ¹° ºÐÀÚ¸¦ ÀÒÀ¸¸é¼­ ÃàÇÕÇÏ¿© ÀÌ·ç´Â ¾Æ¹Ìµå °áÇվƹ̳ë»êÀÇ ¼ö°¡ 2, 3, ¡¦ ÀΠ°æ¿ì, °¢°¢ µðÆéƼµå, Æ®¸®ÆéƼµå, ¡¦µîÀ¸·Î ºÎ¸£¸ç, ¿©·¯ °³ÀÇ ¾Æ¹Ì³ë»êÀ¸·Î ±¸¼ºµÇ´Â °ÍÀ» ¿Ã¸®°íÆéƼµå, À̺¸´Ù Å« °ÍÀ» Æú¸®ÆéƼµå¶ó°í ÇÑ´Ù. Á÷¼â»óÀÇ °ÍÀÌ ¸¹Áö¸¸, È¯»ó ±¸Á¶¸¦ °®´Â ÆéƼµåµµ ÀÖ´Ù. ÀúºÐÀÚÀÇ ÆéƼµå´Â ¹°, »ê, ¾ËÄ®¸® µûÀ§¿¡ Àß ³ì°í ¾ËÄڿÿ¡´Â ³ìÁö ¾ÊÀ¸³ª, °íºÐÀÚÀÇ ÆéƼµå´Â ¹°¿¡ Àß ³ìÁö ¾Ê°í ´Ü¹éÁú°ú ¼ºÁúÀÌ ºñ½ÁÇÏ´Ù. ³úÇϼöüȣ¸£¸ó, ºê¶óµðŰ´Ñ µî°ú °°ÀÌ »ý¸®Àû±â´ÉÀÌ ÇöÀúÇÑ °ÍÀº »ý¸®È°¼ºÆéƼµå(bioactive peptide)¶ó°í ÇÑ´Ù.
¿µ¹® activation ÇÑ±Û È°¼º, Ȱ¼ºÈ­
¼³¸í   
  ÀϹÝÀûÀ¸·Î, »ýü³ª »ýü ¹°ÁúÀÌ ±× ±â´ÉÀ» È°¹ßÇϰԠ³ªÅ¸³»°Ô µÇ´Â °Í, ¿¹¸¦ µé¸é ¨ç Ã˸Šµî¿¡¼­, ±× Ç¥¸é »óÅÂÀÇ º¯È­³ª, ´Ù¸¥ ¹°ÁúÀǠ÷°¡ µî¿¡ ÀÇÇÏ¿©, ±× ±â´ÉÀÌ ÇöÀúÇϰԠ³ô¾ÆÁö´Â °Í. ¨è È¿¼ÒÀü±¸Ã¼ÀǠȰ¼ºÈ­·Î¼­ È¿¼ÒÀÛ¿ëÀ» °¡ÁöÁö ¾Ê´Â È¿¼Ò Àü±¸Ã¼°¡ È°¼ºÀִ ȿ¼Ò·Î º¯È­´Â °Í. ¶Ç È²È­¼ö¼Ò³ª ½Ã¾ÈÈ­¼ö¼Ò»ê µîÀ¸·Î ÆÄÆÄÀÎÀ̠Ȱ¼ºÈ­µÇ´Â °æ¿ìµµ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • atrial natriuretic peptide
    ½É¹æ³ªÆ®·ýÀÌ´¢ÆéƼµå
  • brain natriuretic peptide
    ³ú³ªÆ®·ýÀÌ´¢ÆéƼµå
  • calcitonin gene-related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • gastrin-releasing peptide
    °¡½ºÆ®¸°À¯¸®ÆéƼµå
  • glucagon-like insulinotropic peptide
    ±Û·çÄ«°ïÀ¯»çÀν¶¸°ÀÚ±ØÆéÆ¼µå
  • glucagon-like peptide
    ±Û·çÄ«°ïÀ¯»çÆéƼµå
  • peptide
    ÆéƼµå
  • peptide bond
    ÆéƼµå°áÇÕ
  • peptide linkage
    ÆéƼµå°áÇÕ
  • signal peptide
    ½ÅÈ£ÆéƼµå
  • activation
    Ȱ¼ºÈ­
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®, ¹æ»çÈ­ºÐ¼®
  • activation energy
    Ȱ¼ºÈ­¿¡³ÊÁö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • activation gate
    °³¹æ°ü¹®
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • trypsinogen
    Æ®¸³½Ã³ë°Õ
  • activation
    Ȱ¼º, Ȱ¼ºÈ­, ´Éµ¿È­
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • peptide
    ÆéƼµå
  • atrial natriuretic peptide
    ½É¹æ³ªÆ®·ýÀÌ´¢ÆéƼµå
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • trypsinogen
    Æ®¸³½Ã³ë°Õ
  • brain natriuretic peptide
    ³ú³ªÆ®·ýÀÌ´¢ÆéƼµå
  • peptide bond
    ÆÕƼµå°áÇÕ
  • gastrin-releasing peptide
    °¡½ºÆ®¸°À¯¸®ÆéƼµå
  • peptide linkage
    ÆéƼµå°áÇÕ
  • peptide
    ÆéƼµå
  • signal peptide
    ½ÅÈ£ÆéƼµå
  • activation
    Ȱ¼º, Ȱ¼ºÈ­
  • activation detector
    Ȱ¼ºÈ­Å½Áö±â
  • activation energy
    Ȱ¼º¿¡³ÊÁö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • activation gate
    °³¹æ°ü¹®
  • activation process
    Ȱ¼ºÈ­°úÁ¤
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®, ¹æ»çÈ­ºÐ¼®
  • complement activation
    µµ¿òüȰ¼º, º¸Ã¼È°¼º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • BNP=> brain natriuretic peptide
    ³ú ³ªÆ®·ý ÀÌ´¢ ÆéƼµå
  • GIP (Gastric inhibitory peptide)
    À§Àå¾ïÁ¦(êÖíóåäð¤) ÆéŸÀ̵å
  • GRP (Gastrin-releasing peptide)
    °¡½ºÆ®¸°-ºÐºñÆéÆÄÀ̵å
  • Gastric inhibitory peptide
    À§¾ïÁ¦(êÖåäð¤)È£¸£¸ó
  • Gastrin-releasing peptide
    °¡½ºÆ®¸°ºÐºñÆéŸÀ̵å
  • VIP : vasoactive intestinal peptide
    Ç÷°üÀÛ¿ë ¼ÒÀåÆéŸÀ̵å.
  • VIP = vasoactive intestinal (poly)peptide
    Ç÷°üÀۿ뼺 ÀåÆéƼµå
  • procollagen III peptide
    ÇÁ·ÎÄݶó°Õ III ÆéƼµå
  • activation
    Ȱ¼ºÈ­(üÀàõûù).
  • activation
    Ȱ¼ºÈ­
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®(¡­ÝÂà°), ¹æ»çÈ­(Û¯ÞÒûù)ºÐ¼®.
  • activation analysis
    ¹æ»çÈ­ºÐ¼®, Ȱ¼ºÈ­ºÐ¼®
  • activation detector
    Ȱ¼ºÈ­ ŽÁö±â
  • activation energy
    Ȱ¼ºÈ­¿¡³ÊÁö
  • activation gate
    °³¹æ °ü¹®(ËÒÛÁμڦ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • trypsinogen activation peptide(TAP)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • trypsinogen
    Æ®¸³½Ã³ëÁ¨, Æ®¸³½Ã³ë°Õ
  • trypsinogen
    Æ®¸³½Ã³ëÀü.
  • atrial natriuretic peptide
    ½É¹æ³ªÆ®·ýÀÌ´¢ÆéŸÀ̵å, ½É¹æ³ªÆ®·ýÀÌ´¢ÆéƼµå
  • brain gut peptide
    ³úÀå °üÆéƼµå.
  • brain gut peptide
    ³úÀå °üÆéƼµå.
  • brain gut peptide
    ³úÀå°üÆéƼµå
  • brain natriuretic peptide
    ³ú ³ªÆ®·ý ÀÌ´¢ ÆéƼµå
  • brain peptide
    ³úÆéƼµå.
  • c-peptide
    ¾¾-ÆéŸÀ̵å, ¾¾-ÆéƼµå
  • c-peptide
    c ÆéƼµå
  • c-peptide measurement
    c ÆéƼµåÃøÁ¤
  • calcitonin-gene related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • endogenous opiate peptide
    ³»À缺 ¿ÀÇÇ¿¡ÀÌÆ® ÆéŸÀ̵å, ³»À缺 ¾ÆÆí¾ç ÆéŸ À̵å.
  • neuro-peptide
  • opioid peptide
    ¾ÆÆí¾çÆéƼµå<ÆéŸÀ̵å>.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • activation
    Ȱ¼ºÈ­ (üÀàõûù)
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼® (üÀàõûùÝÂà°)
  • activation energy
    Ȱ¼ºÈ­(üÀàõûù)¿¡³ÊÁö
  • activation stage
    Ȱ¼ºÈ­±â(üÀàõûùÑ¢)
  • amino acid activation
    ¾Æ¹Ì³ë»ê(ß«) Ȱ¼ºÈ­(üÀàõûù)
  • Arrenius activation energy
    ¾Æ·¹´Ï¿ì½º Ȱ¼º(üÀàõ)¿¡³ÊÁö
  • complement activation
    º¸Ã¼ Ȱ¼ºÈ­(ÜÍô÷üÀàõûù)
  • contact activation cofactor
    "Á¢ÃËȰ¼º º¸ÀÎÀÚ(ïÈõºüÀàõÜÍì×í­), (ÔÒ) high molecular weight kininogen"
  • energy of activation
    Ȱ¼ºÈ­(üÀàõûù) ¿¡³ÊÁö
  • fatty acid activation
    Áö¹æ»ê Ȱ¼ºÈ­ (ò·Û¸ß«üÀàõûù)
  • feed-forward activation
    ¾Õ¸ÔÀÓ È°¼ºÈ­ (üÀàõûù)
  • gene activation
    À¯ÀüÀÚ È°¼ºÈ­(ë¶îîí­üÀàõûù)
  • macrophage activation factor
    ´ë½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ(ÓÞãÝá¬øàüÀàõì×í­)
  • neutron activation alalysis
    Áß¼ºÀÚ ¹æ»çÈ­ºÐ¼®(ñéàõí­Û¯ÞÒûùÝÂà°)
  • reciprocal activation
    »óº¸ Ȱ¼ºÈ­(ßÓÜÍüÀàõûù)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
BTg bovine trypsinogen
C-Peptide Connecting Peptide
ERP early receptor potential; effective refractory period; elodoisin-related peptide; endoscopic retrogr...
VIP vasoactive intestinal peptide; vasoinhibitory peptide; venous impedance plethysmography; ventricular...
RAS   1) Reticular Activating(Activation) System
  2) Renal Artery Stenosis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
TAP Trypsinogen activation peptide
IRT Immunoreactive trypsinogen
C-peptide connecting peptide
Kact Activation constants
AD activation domain
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • trypsinogen
    Æ®¸³½Ã³ë°Õ
  • activation
    Ȱ¼ºÈ­
    Ȱ¼ºÈ­ÇÏ´Â ÀÛ¿ëÀ̳ª °úÁ¤.
  • activation of muscle
    ±ÙÀ°ÀÇ È°¼ºÈ­
    ±ÙÀ° Á¶Á÷À¸·Î ¿¡³ÊÁö°¡ ¹æÃâµÇ¾î ±ÙÀ°ÀÇ ¼öÃàÀ» ÀÏÀ¸Å°´Â °Í.
  • activation process
    Ȱ¼ºÈ­ °úÁ¤
  • co-activation
    »óÈ£ Ȱ¼º
  • complement activation
    º¸Ã¼ Ȱ¼º ÀÛ¿ë, º¸Ã¼ Ȱ¼ºÈ­
  • heat of activation
    Ȱ¼ºÈ­ ¿­
  • polyclonal activation
    ´Ù¼ö Ŭ·Ð Ȱ¼º
  • receptor activation
    ¼ö¿ëü Ȱ¼ºÈ­, ¼ö¿ë±â Ȱ¼ºÈ­
  • secondary activation
    ÀÌÂ÷Àû Ȱ¼º
  • sympathetic activation
    ±³°¨½Å°æ°è Ȱ¼º
  • 9-amino acid peptide
    9-¾Æ¹Ì³ë»ê ÆéŸÀ̵å
  • brain peptide
    ³ú ÆéƼµå
  • corticotropin-like intermediate lobe peptide

    corticotropin-releasing factor (ºÎ½Å ÇÇÁú È£¸£¸ó À¯¸® ¿ä¼Ò, ºÎ½Å ÇÇÁú È£¸£¸ó À¯¸® ÀÎÀÚ

  • dynorphin-related peptide
    ´ÙÀ̳îÇÉ °ü·Ã ÆéƼµå
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
trypsinogen <physiology> The antecedent of trypsin, a substance which is contained in the cells of the pancreas and gives rise to the trypsin.
Origin: Trypsin + -gen.
Source: Websters Dictionary
(01 Mar 1998)
activation <radiobiology> Activation occurs when a particle interacts with an atomic nucleus, shifting the nucleus into an unstable state, and causing it to become radioactive.
In fusion research, where deuterium-tritium is a common fuel mixture, the neutron released when (D + T) combine to form (4He + n) can activate the reactor structure. In this case the 4He is inert, the neutron sticks to another nucleus, and the neutron + nucleus reaction creates an actvation product. Sometimes called radioactivation.
See: activation product, activation analysis.
(09 Oct 1997)
activation analysis <radiobiology> Method for identifying and measuring chemical elements in a sample of material. Sample is first made radioactive by bombardment with neutrons, charged particles, or gamma rays.
Newly formed radioactive atoms in the sample then give off characteristic radiations (such as gamma rays) that tell what kinds of atoms are present, and how many.
(09 Oct 1997)
activation energy <chemistry> The amount of energy (expressed in joules) that is needed to convert all the molecules in one mole of a reacting substance from a ground state to the transition state.
(06 May 1997)
activation product <radiobiology> The unstable nucleus formed when activation occurs. (See activation above.)
(09 Oct 1997)
amino acid activation The first step of protein synthesis, whereby an amino acid reacts with adenosine triphosphate in the presence of aminoacyl RNA synthetase to produce an amino acid adenylate, which provides the energy necessary for the attachment of the amino acid to a specific transfer RNA molecule.
(12 Dec 1998)
macrophage activation The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (maf) and the macrophage migration-inhibitory factor (mmif), immune complexes, c3b, and various peptides, polysaccharides, and immunologic adjuvants.
(12 Dec 1998)
gene activation The process of activation of a gene so that it is expressed at a particular time. This process is crucial in growth and development.
(05 Mar 2000)
Gibbs energy of activation The Gibbs energy that must be added to that already possessed by a molecule or molecules in order to initiate a reaction.
(05 Mar 2000)
virus activation The mechanism by which latent viruses, such as genetically transmitted tumour viruses or prophages of lysogenic bacteria, are induced to replicate and are released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell lipopolysaccharides, glucocorticoid hormones, halogenated pyrimidines, ionizing radiation, ultraviolet light, and superinfecting viruses.
(12 Dec 1998)
cis activation <molecular biology> Activation of a gene by an activator located on the same chromosome i.e. Not by a diffusible product.
(18 Nov 1997)
complement activation The sequential activation of serum components c1 through c9, initiated by an erythrocyte-antibody complex or by microbial polysaccharides and properdin, and producing an inflammatory response.
(12 Dec 1998)
platelet activation A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable haemostatic plug.
(12 Dec 1998)
neutron activation analysis Activation analysis in which the specimen is bombarded with neutrons. Identification is made by measuring the resulting radioisotopes.
(12 Dec 1998)
neutrophil activation The process in which the neutrophil is stimulated by diverse substances, resulting in degranulation and/or generation of reactive oxygen products, and culminating in the destruction of invading pathogens. The stimulatory substances, including opsonised particles, immune complexes, and chemotactic factors, bind to specific cell-surface receptors on the neutrophil.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • peptide
    ÆéŸÀ̵å;µÑ ÀÌ»óÀÇ ¾Æ¹Ì³ë»ê °áÇÕ¹°
  • activation
    Ȱµ¿ÀûÀ¸·Î Çϱâ;Ȱ¼ºÈ­;ºÎ´ë ½Å¼³(Æí¼º)
  • neutron activation analysis
    Áß¼ºÀÚ(À¯µµ)¹æ»çÈ­ ºÐ¼®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á